Key result
Serum ADMA levels are ~52% higher in patients with CAD versus healthy controls.
Why the study?
Asymmetric dimethylarginine may reflect early changes in vascular health, but its role in coronary artery disease is still being explored.
Are serum ADMA levels elevated in patients with CAD compared to healthy controls, and do they correlate with angiographic severity?
Case-Control (n=60)
No
Are serum ADMA levels elevated in patients with CAD compared to healthy controls, and do they correlate with angiographic severity?
Absolute Event Rate: 0.82% vs 0.54%
p-value: p=<0.001
Serum ADMA levels are significantly elevated in CAD patients and show a trend toward increasing with angiographic severity, supporting its potential role as a marker of endothelial dysfunction.
No takes yet. Share an insight, caveat, or question.
Supports ADMA as endothelial dysfunction marker in CAD; hypothesis-generating for severity correlation pending validation.
Shambhavi et al. (2026) conducted a case-control in Coronary Artery Disease (n=60). Asymmetric dimethylarginine (ADMA) measurement vs. Healthy matched controls was evaluated on Serum ADMA levels (µmol/L) (p=<0.001). Mean serum asymmetric dimethylarginine levels were significantly higher in patients with coronary artery disease compared to healthy controls (0.82 vs 0.54 µmol/L).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: